Bayer’s Pharma Pipeline Flexes as Supreme Court Weighs a $30 Billion Legal Sword

Bayer shares surge above key moving average after ex-dividend dip, driven by 68% sales jump in new drugs Nubeqa and Kerendia, while Supreme Court weighs Roundup pre-emption ruling.

Bayer’s stock has staged a sharp recovery from its intraday lows, clawing back above a key technical level as investors juggle two vastly different narratives: a pharma division firing on all cylinders and a legal overhang that could reshape the company’s balance sheet. After dipping toward €36 in morning trading on Thursday, the shares surged 4.39% to close at €38.05, comfortably reclaiming their long-term moving average. The bounce comes just a day after the stock absorbed an ex-dividend adjustment, though it remains roughly 7% lower on a weekly basis.

New Drugs Deliver a 68% Sales Surge

While the courtroom drama captures headlines, Bayer’s management is quietly touting progress in the lab. The company’s strategy of replacing revenue from aging patents is gaining traction, with two key products leading the charge. Cancer drug Nubeqa and kidney treatment Kerendia together posted a 68% jump in sales over the past fiscal year. The momentum extends beyond those blockbusters: heart medication Beyonttra has exceeded internal expectations since its launch, and hormone-free menopause treatment Lynkuet is now gearing up for a European rollout after its U.S. debut.

These operational bright spots are crucial as Bayer navigates a period of financial strain. The group’s net debt stood at nearly €30 billion, and the recent payout of a minimum dividend of €0.11 per share—barely a token—underscores the cash constraints. Chief Executive Bill Anderson’s restructuring plan now faces heightened scrutiny, with investors demanding measurable progress in streamlining operations over the coming months.

The Supreme Court’s Pivotal Pre-emption Question

The legal cloud hanging over Bayer centers on a single, high-stakes question: does federal law override state-level labeling requirements for the herbicide Roundup? The U.S. Supreme Court heard oral arguments on Monday in the case Durnell v. Monsanto, and observers describe a deeply divided bench. The ruling, expected by the end of the court’s session in June, will determine the fate of more than 100,000 outstanding lawsuits.

Provisions for legal claims already weigh on the balance sheet at roughly €11.8 billion, and analysts at UBS recently downgraded the probability of a favorable outcome for Bayer to 70%. Some plaintiffs are reportedly resisting a potential multi-billion-dollar settlement, keeping the litigation risk alive. The sheer scale of the exposure—potentially running into tens of billions—means the verdict could either unlock significant shareholder value or deepen the company’s financial hole.

Analyst Targets Signal Anticyclical Opportunity

Despite the uncertainty, a majority of financial institutions see value in Bayer’s current valuation. The median price target sits at roughly €50, implying upside of about 34.4% from Thursday’s close. Goldman Sachs leads the bull camp at €55, followed by UBS at €52, JPMorgan at €50, Barclays at €48, and Deutsche Bank at €43. UBS analyst Matthew Weston describes the current entry point as an anticyclical buying opportunity, though he acknowledges the legal overhang.

Q1 Results on the Horizon

Operationally, Bayer’s fourth-quarter performance offered a mixed bag. Earnings per share of €0.62 beat expectations, but revenue slipped to €11.44 billion. The market now looks ahead to first-quarter results, due on May 12, where the focus will be on profit margins in the core agriculture division, Crop Science, and signs of improving profitability across the group.

For Bayer, the coming weeks represent a delicate balancing act. A favorable Supreme Court ruling could unleash a wave of investor optimism, while a defeat would test the resilience of both the balance sheet and the share price. In the meantime, the pharma pipeline is doing its part to keep the narrative from turning entirely sour.